SCHEMBL16626780

SCHEMBL16626780

CNCc1cn(S(=O)(=O)c2cccc(OC(F)F)c2)c2cc(-c3cnc(OC)nc3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
RORC P51449 7/20 0.48
BRD4 O60885 1/20 0.44
HTR6 P50406 6/20 0.39
DRD2 P14416 1/20 0.36
KDM2B Q8NHM5 1/20 0.35
GRIN1 Q05586 2/20 0.35
GRIN2B Q13224 2/20 0.35
RXRA P19793 1/20 0.35
MET P08581 1/20 0.35
PTGES2 Q9H7Z7 1/20 0.34
SCN9A Q15858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16618781 0.99 RORC (0.48) RORCBRD4HTR6DRD2KDM2B
SCHEMBL16626779 0.89 RORC (0.50) RORCBRD4HTR6KDM2BGRIN1
Hydrochloric Acid SCHEMBL16618992 0.88 RORC (0.49) RORCBRD4HTR6KDM2BGRIN1
SCHEMBL17971574 0.87 RORC (0.49) RORCBRD4HTR6KDM2BGRIN1
Hydrochloric Acid SCHEMBL16618537 0.86 RORC (0.48) RORCBRD4HTR6DRD2KDM2B
SCHEMBL17971573 0.86 RORC (0.51) RORCBRD4HTR6KDM2B
Hydrochloric Acid SCHEMBL16619011 0.85 RORC (0.50) RORCBRD4HTR6DRD2KDM2B
SCHEMBL17971571 0.83 HTR6 (0.39) RORCHTR6DRD2PTGES2
Hydrochloric Acid SCHEMBL16618836 0.82 HTR6 (0.38) HTR6DRD2PTGES2
SCHEMBL16626632 0.81 RORC (0.49) RORCBRD4HTR6KDM2BMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI RORC 1067/4885BRD4 2190/4885HTR6 166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.